Geron Secures up to $375 Million in Funding with Royalty Pharma, Pharmakon Advisors

MT Newswires Live2024-11-08

Geron (GERN) said Thursday it secured up to $375 million in synthetic royalty and debt financings with Royalty Pharma (RPRX) and investment funds managed by Pharmakon Advisors.

The company said $250 million in cash was provided at closing, with another $125 million in debt available.

Royalty Pharma has provided $125 million at closing and will receive tiered royalty payments on US net sales of Geron's Rytelo treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia.

Geron said investment funds managed by Pharmakon have committed to a five-year senior secured term loan of up to $250 million, with a first tranche of $125 million drawn at closing.

The company used part of the proceeds to fully repay amounts owned under its existing loan with Hercules Capital and Silicon Valley Bank.

Geron can draw a second tranche of $75 million and a third tranche of $50 million, if requested, before Dec. 31, 2025, the company said.

Price: 4.29, Change: +0.02, Percent Change: +0.35

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481132706?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 00:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481132706","market":"nz","top_or_hot":-1,"title":"Geron Secures up to $375 Million in Funding with Royalty Pharma, Pharmakon Advisors","media":"MT Newswires Live","content":"<html><body><p> Geron (GERN) said Thursday it secured up to $375 million in synthetic royalty and debt financings with Royalty Pharma (RPRX) and investment funds managed by Pharmakon Advisors.</p><p>The company said $250 million in cash was provided at closing, with another $125 million in debt available.</p><p>Royalty Pharma has provided $125 million at closing and will receive tiered royalty payments on US net sales of Geron's Rytelo treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia.</p><p>Geron said investment funds managed by Pharmakon have committed to a five-year senior secured term loan of up to $250 million, with a first tranche of $125 million drawn at closing.</p><p>The company used part of the proceeds to fully repay amounts owned under its existing loan with Hercules Capital and Silicon Valley Bank.</p><p>Geron can draw a second tranche of $75 million and a third tranche of $50 million, if requested, before Dec. 31, 2025, the company said.</p><p>Price: 4.29, Change: +0.02, Percent Change: +0.35</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Geron Secures up to $375 Million in Funding with Royalty Pharma, Pharmakon Advisors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGeron Secures up to $375 Million in Funding with Royalty Pharma, Pharmakon Advisors\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 00:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Geron (GERN) said Thursday it secured up to $375 million in synthetic royalty and debt financings with Royalty Pharma (RPRX) and investment funds managed by Pharmakon Advisors.The company said $250 ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2481132706","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481132706","pubTimestamp":1730997734,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Geron  said Thursday it secured up to $375 million in synthetic royalty and debt financings with Royalty Pharma  and investment funds managed by Pharmakon Advisors.The company said $250 million in cash was provided at closing, with another $125 million in debt available.Royalty Pharma has provided $125 million at closing and will receive tiered royalty payments on US net sales of Geron's Rytelo treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia.Geron said investment funds managed by Pharmakon have committed to a five-year senior secured term loan of up to $250 million, with a first tranche of $125 million drawn at closing.The company used part of the proceeds to fully repay amounts owned under its existing loan with Hercules Capital and Silicon Valley Bank.Geron can draw a second tranche of $75 million and a third tranche of $50 million, if requested, before Dec. 31, 2025, the company said.Price: 4.29, Change: +0.02, Percent Change: +0.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","RPRX":"Royalty Pharma plc","BK4139":"生物科技","GERN":"杰龙"},"translate_title":"Geron从Royalty Pharma和Pharmakon Advisors获得高达3.75亿美元的资金","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GERN":1,"RPRX":0.9},"content_text":"Geron (GERN) said Thursday it secured up to $375 million in synthetic royalty and debt financings with Royalty Pharma (RPRX) and investment funds managed by Pharmakon Advisors.The company said $250 million in cash was provided at closing, with another $125 million in debt available.Royalty Pharma has provided $125 million at closing and will receive tiered royalty payments on US net sales of Geron's Rytelo treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia.Geron said investment funds managed by Pharmakon have committed to a five-year senior secured term loan of up to $250 million, with a first tranche of $125 million drawn at closing.The company used part of the proceeds to fully repay amounts owned under its existing loan with Hercules Capital and Silicon Valley Bank.Geron can draw a second tranche of $75 million and a third tranche of $50 million, if requested, before Dec. 31, 2025, the company said.Price: 4.29, Change: +0.02, Percent Change: +0.35","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481132706"}